Hello and welcome to the details of US FDA warns about counterfeit versions of Novo's diabetes drug Ozempic and now with the details
Nevin Al Sukari - Sana'a - Danish drugmaker Novo Nordisk and the FDA are testing the seized products and do not yet have information about the drugs' identity, quality or safety, the agency said. — Reuters pic
WASHINGTON, Dec 22 ― The US Food and Drug Administration yesterday warned consumers not to use counterfeit versions of Novo Nordisk's diabetes drug Ozempic that have been found in the country's drug supply chain.
The health regulator said it will continue to investigate counterfeit Ozempic 1 milligram injections and has seized thousands of units, but flagged that some may still be available for purchase.
Danish drugmaker Novo Nordisk and the FDA are testing the seized products and do not yet have information about the drugs' identity, quality or safety, the agency said.
Advertisement
Novo said the seizures took place in warehouses outside the company's authorised supply chain.
The agency said the needles from the seized injections are counterfeit and their sterility cannot be confirmed, which presents an additional risk of infection for patients.
Other confirmed counterfeit components from the seized products include the pen label and accompanying information about the healthcare professional and patient as well as the carton.
Advertisement
The FDA urged drug distributors, retail pharmacies, healthcare practitioners and patients to check the drug they have received and to not distribute, use or sell the units labelled with lot number NAR0074 and serial number 430834149057.
The regulator said it was aware of five adverse events resulting from use of the drug belonging to this lot, but all of them were consistent with known side-effects related to authentic Ozempic.
Demand for Wegovy and Ozempic is exceeding Novo's supply of the drugs in the United States, Germany and Britain, leading the company to restrict supplies of certain doses of Wegovy to the US market.
Though only Wegovy is approved for obesity, its diabetes counterpart Ozempic also leads to dramatic weight loss, which has led people in the United States and Europe to use the drug “off-label”, meaning not for its approved use. ― Reuters
These were the details of the news US FDA warns about counterfeit versions of Novo's diabetes drug Ozempic for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
